Selexis SA to Present and Partner at the BioPharm America 2011 Partnering Conference

Andrew Sandford, will present, “From Candidate Discovery to Product Development: Improving Drug Discovery with Selexis' Next Generation of SUREtechnologies” on Thursday, September 8, 2011 at 1:45 PM at the BioPharma America Partnering Conference being held February 7-9, 2011, at the Westin Boston Waterfront in Boston, Massachusetts.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell l
From Candidate Discovery to Product Development: Improving Drug Discovery with Selexis' Next Generation of SUREtechnologies.

Geneva, Switzerland (PRWEB) August 30, 2011

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today the Company’s vice president of business development and licensing, Andrew Sandford, will present, “From Candidate Discovery to Product Development: Improving Drug Discovery with Selexis' Next Generation of SUREtechnologies” on Thursday, September 8, 2011 at 1:45 PM at the BioPharma America Partnering Conference being held February 7-9, 2011, at the Westin Boston Waterfront in Boston, Massachusetts. The Company will be also taking part in the pre-scheduled partnering meetings.

Companies or individuals attending BioPharm America can schedule meetings with Selexis (registration required) by visiting: ebdgroup.com/bpa/partnering/index.php

Selexis Partnering Schedule:
Thursday, September 8, 2011     8:00 AM – 6:00 PM ET
Friday, September 9, 2011     8:00 AM – 3:00 PM ET

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.
For more information, visit http://www.selexis.com

About BioPharm America
BioPharm America™ is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, the world’s leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

For more information, visit http://www.ebdgroup.com/bpa.

###


Contact

Attachments

Selexis Logo Selexis Logo

Selexis Corporate Logo


Andrew Sandford, Selexis VP Business Development and Licensing Andrew Sandford, Selexis VP Business Development and Licensing

Andrew Sandford, Selexis VP Business Development and Licensing


Drug Discovery, Cell Line Development, Manufacturing, Therapeutic Proteins

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins